Ulti_1170x120_5-11-20

CVS applauds introduction of key legislation for kidney transplant patients

Print Friendly, PDF & Email
WOONSOCKET, R.I. — CVS Health issued the following statement this week regarding the introduction of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019 in the United States Congress:

“Tens of thousands of people in the United States have kidney transplants each year and taking immunosuppressant medications is key to the success of each patient’s journey. Unfortunately, when kidney patients are without health coverage, they too often stop taking these medications and in turn, redevelop kidney failure.  CVS Health applauds reintroduction of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019, legislation that ensures kidney transplant patients can maintain access to Medicare Part B coverage for immunosuppressant drugs after it currently expires, if no other coverage is available.

As a company committed to patient-centric and clinically-optimal kidney care, we support policies like these that have the potential to improve the lives of kidney disease patients. CVS Health is focused on reshaping the patient experience through CVS Kidney Care and will continue to advance new kidney disease management programs while also developing new technologies to treat kidney failure. We applaud Representatives Michael Burgess (R, Texas) and Ron Kind (D, Wis.) for championing this important legislation.”


EMC_728x90

TRP_728x90_12-19-19

Comments are closed.